Clinical Trial

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is an interventional phase II clinical trial aiming to evaluate the efficacy and safety of KN046, a PD-L1 and CTLA-4 bispecific antibody, in combination with regorafenib or apatinib for microsatellite instability-high digestive system cancers resistant to PD-1/PD-L1 blockade. KN046 plus regorafenib will be given for patients with colorectal cancers, and KN046 plus apatinib will be given for patients with gastric cancers (including esophageal-gastric junction cancers) and other kinds of digestive system cancers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-20.
Trial Details
NCT Number NCT06099821
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Digestive System Cancers
Enrollment 39 participants
Start Date 2023-10-25
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-26